Analytical Data
-
Gene name
MAGED2
- Application
-
Alternative Names
JCL-1; BCG1; 11B6; MAGE-D2; HCA10; MAGED; Hepatocellular Carcinoma Associated Protein; Breast Cancer Associated Gene 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UNF1
-
Expression Region
Leu279~Ala478
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MAGED2, a member of the MAGE (melanoma antigen gene) family, has garnered significant attention in recent years due to its potential implications in cancer biology and immunotherapy. Initially identified for its expression in melanoma, MAGED2 is a cancer/testis antigen, meaning it is normally expressed in the testes but abnormally expressed in various tumor types, making it a promising target for cancer immunotherapy. The unique expression pattern of MAGED2 raises interest in its role in tumorigenesis and immune evasion, as it may facilitate the development of tumor-selective therapies that harness the immune system to target cancer cells. Furthermore, research indicates that MAGED2 may contribute to the regulation of key cellular processes, including cell proliferation and apoptosis, thereby influencing the progression of malignancies. Understanding the structure and function of MAGED2 at the molecular level can provide crucial insights into its role in cancer and help in developing diagnostic, prognostic, and therapeutic strategies. The ongoing investigations into MAGED2 involve the characterization of its protein interactions, epitope mapping for vaccine development, and exploring its potential as a biomarker for specific cancers. As the field of cancer immunology advances, MAGED2 stands out as a candidate for innovative treatment modalities, underscoring the importance of elucidating its biological functions and mechanisms in cancer pathology.
